A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Фаза 1/2
Завершено
NCT04075396
| Заболевание | Carcinoma, Non-Small-Cell Lung |
|---|
| Фаза | Фаза 1/2 |
|---|
| Спонсор | Janssen Research & Development, LLC |
|---|
| Статус | Завершено |
|---|
| Участники | 29 участн. |
|---|
| Вмешательство | Lazertinib |
|---|
| Дата начала | 16.10.2019 |
|---|
| Дата завершения | 8.01.2021 |
|---|
| Публикация результатов | 28.02.2024 |
|---|
Кратко
The main purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of Lazertinib when given orally to participants with epidermal growth factor receptor single activating mutation positive (EGFRm+) locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC).
Part D: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
From Day 1 up to 14 months · Participants
| Lazertinib 240 mg | 15 Participants |
|---|
| Lazertinib 320 mg | 13 Participants |
|---|
Part D: Number of Participants With Clinically Significant Abnormalities in Vital Signs
From Day 1 up to 14 months · Participants
| Lazertinib 240 mg | 0 Participants |
|---|
| Lazertinib 320 mg | 0 Participants |
|---|
Part D: Number of Participants With Clinically Significant Abnormalities in Physical Examination
From Day 1 up to 14 months · Participants
| Lazertinib 240 mg | 8 Participants |
|---|
| Lazertinib 320 mg | 2 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.